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Background and Objectives: About 10-15% of Kawasaki disease (KD) is refractory to intravenous immunoglobu-
lin (IVIG) therapy. This study was designed to investigate the predicting factors for refractory KD. Subjects and 
Methods: We reviewed retrospectively the clinical records of 77 patients with typical KD admitted at Wonju Chris-
tian Hospital from January, 2005, to December, 2008. The variance of laboratory and demographic parameters be-
tween the IVIG-responsive group and IVIG-resistant group were analyzed. Thirteen patients with urinary tract in-
fections were randomly collected as a febrile control group. Results: Among 77 patients diagnosed with complete 
KD, 13 patients (16.9%) were IVIG-resistant. The febrile period and hospital days were significantly longer in 
the IVIG-resistant group than IVIG-responsive group (p<0.001, p=0.002). Serum levels of albumin and sodium 
were significantly lower in the IVIG-resistant group (p=0.025). The Kobayashi score could differentiate these 
two groups (p=0.015). Fewer lymphocytes was observed during the subacute phase in the IVIG-resistant group 
(p=0.032). Coronary arterial dilatations (CADs) were observed in 10.9% (7/64) of IVIG-responders and 38.5% 
(5/13) of IVIG-resistant patients (p=0.038). Conclusion: The percentage of neutrophils and lymphocytes in pa-
tients with KD, in addition to known risk factors for refractory KD, may help predict IVIG-resistance in patients 
with KD. (Korean Circ J 2010;40:239-242) 
 





Kawasaki disease (KD) is subcategory of systemic vas-
culitis that starts after infectious stimuli. Characteristic 
clinical features are prolonged fever, bilateral conjunc-
tival injection, erythematous induration of palms and 
soles, mucocutaneous changes of oropharynx and lips, 
polymorphous skin rashes, and cervical lymphadenopa-
thy.
1) The incidence of KD has increased in Japan, re-
aching 174.0 per 100,000 in 2004, for children younger 
than 5 years of age.
2) KD is a leading cause of acquired 
heart disease in children in the developed countries.
3) 
Coronary arterial lesions develop in less than 5 percent 
of cases after high dose intravenous immunoglobulin 
(IVIG) treatment.
4) However, 10-15% of KD patients 
show persistent fever despite high dose IVIG treatment 
(2 g/kg),
5) a condition known as refractory KD. As the 
incidence of KD has increased, refractory KD also has 
also increased.
5-7) A higher portion of band counts, lower 
serum levels of albumin, abnormal findings in initial 
echocardiography,
8) hyponatremia, early treatment within 
4 days of fever, elevated aspartate aminotransferase (AST), 
high proportion of neutrophils, C-reactive protein (CRP) 
≥10 mg/dL, younger than 12 months old, thrombocy-
topenia,
7) and recurrent KD
9) are known risk factors for 
refractory KD. Most risk factors are related to severe in-
flammatory reactions and are not suppressed by IVIG 
alone. Furthermore, in addition to pro-inflammatory cy-
tokines, growth factors such as vascular endothelial grow-
th factors or platelet-derived growth factor and chemo-
kines are also involved in the pathogenesis of KD.
10) 
Kobayashi et al.
7) suggested a useful scoring system that 
can predict refractory KD. This scoring system reflects 
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clinical data as the consequences of increased inflamma-
tory cascades. Other predictive factors are still needed.   
Genetic defects in the apoptosis of immune cells may 
contribute to the poor responsiveness to IVIG during 
the acute phase of KD.
11) The increased percentage of 
neutrophils may reflect apoptotic defects and the con-
sequent restriction of effective clonal expansion of lym-
phocytes against infectious stimuli at the acute phase 
of KD.
11) Therefore, we measured differences in the sub-
population of white blood cells as a potential risk factor 
for refractory KD. 
 
Subjects and Methods 
 
A total of 77 patients who fulfilled the criteria for com-
plete KD at the Wonju Christian Hospital from Janu-
ary, 2005, to December, 2008, were included in this 
study. We retrospectively reviewed clinical records of 
these patients. The criteria for the diagnosis of complete 
KD followed the 5th revision of the diagnostic guide-
line for KD,
12) and included fever (body temperature 
>38℃) for at least 5 days accompanied by the presence 
of at least 4 of these 5 findings: bilateral conjunctival in-
jection, changes in the lips and oral cavity, nonpurulent 
cervical lymphadenopathy, polymorphous rashes, and 
changes in the extremities.   
Among 77 patients, 13 patients (16.9%) were treated 
twice with IVIG. The age at disease onset ranged from 
3 months to 8 years (median age 2.49 years). All patients 
were treated with 2 g/kg of IVIG along with aspirin (60 
mg/kg/day) at the acute phase of KD.   
Patients were classified into two groups: IVIG-resis-
tant patients required a second dose of IVIG because of 
a reappearance of fever within 48 hours after the initial 
IVIG treatment. The IVIG-responsive group became afe-
brile after receiving a single dose of IVIG treatment and 
showed marked improvement of the initial inflamma-
tory indices. Thirteen randomly selected age- and sex-
matched febrile patients with urinary tract infections were 
adopted as the febrile control group. 
Laboratory variables (complete blood count with dif-
ferential count, AST, alanine aminotransferase, serum 
levels of albumin and sodium, erythrocyte sedimenta-
tion rate and CRP) were analyzed along with demogra-
phic variables (gender, age in months, hospital stay and 
days of illness at initial treatment). Laboratory data were 
obtained before IVIG treatment (acute phase) and 7 days 
after the initial IVIG treatment (subacute phase). 
We used the scoring model established by Kobaya-
shi et al.
7) for predicting IVIG-resistance: high serum 
levels of AST, CRP, high percentage of neutrophils, yo-
ung age at disease onset, low serum levels of sodium, 
low platelet counts and early administration of IVIG in 
the course of illness are independent risk factors. The 
points scored for each variable were as follows: sodium 
≤133 mmol/L, 2 points; days of illness at initial treat-
ment  ≤4, 2 points; AST ≥100 IU/L, 2 points; % neu-
trophils  ≥80%, 2 points; CRP  ≥10 mg/dL, 1 point; 





Two-dimensional echocardiography was performed to 
measure coronary artery (CA) size at the time of diag-
nosis. Follow up echocardiograms were performed at 7 
days, 6 months, and 1 year after diagnosis to compare 
the incidence of coronary arterial lesions. CA lesions were 
defined as follows; 1) a coronary arterial luminal dia-
meter exceeded 3 mm in a child <5 years old, or 4 mm 
in a child ≥5 years; 2) an internal segment diameter was 
at least 1.5 times as large as that of an adjacent segment; 




Variables including clinical manifestations, laboratory 
findings, and responses to treatment were analyzed with 
SAS version 9.1 (SAS Institute Inc., Cary, NC, USA) us-
ing the chi-square test and Student’s t-test. For inclusion 
of the control group, we used the one-way analysis of va-




The duration of fever and hospital day were signifi-
cantly longer in the IVIG resistant group than IVIG res-
ponsive group (p<0.001, p=0.002) (Table 1). The IVIG-
resistant group showed lower serum albumin (p=0.025) 
and lower serum sodium (p=0.049). Kobayashi scores 
were significantly higher in the IVIG-resistant group 
than the IVIG-responsive group (p=0.015) (Table 2). 
Both groups had a similar percentage of neutrophils 
and lymphocytes during the acute phase. However, a hi-
gher percentage of neutrophils and a lower percentage 
of lymphocytes were observed in the IVIG-resistant gr-
oup than the IVIG-responsive group or controls during 
the subacute phase (p=0.002, 0.032) (Table 3). Coronary 
Table 1. Demographic characteristics in IVIG-responsive group and IVIG-resistant group in Kawasaki disease 
Parameters  IVIG-responsive group (n=64)  IVIG-resistant group (n=13)  p 
Median age (months)  30.5±22.5 32.6±25.3 0.227
Gender ratio (M : F)  2.0 : 1  1.6 : 1  0.639
Hospital stay (days)  10.6±3.3  14.1±6.0 0.002
Days of illness at initial treatment (days)*  5.9±1.8 6.3±1.6  <0.001
*Days with documented fever before initiation of IVIG treatment. M: male, F: female, IVIG: intravenous immunoglobulin 
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arterial dilatations (CADs) were observed in 10.9% (7/ 
64) of the IVIG-responsive group and in 38.5% (5/13) 
of IVIG-resistant group during the acute phase (p= 
0.038) (Table 4). One patient in the IVIG-resistant group 




Although the cause of KD remains unknown, epi-
demiologic features suggest that it is related to infectious 
agents, and aberrant immune mechanisms may play an 
important role in the pathogenesis of KD.
14) The re-
presentative clinical parameters of IVIG-resistant KD 
are also associated with severe immune reactions after an-
tigenic stimuli.
8)15) 
The scoring system suggested by Kobayashi et al.
7) can 
help predict risk factors for IVIG-resistant KD and lead 
to timely management and better clinical outcomes.
5) 
We also measured subpopulations of leukocytes in pa-
tients with KD.
12)16-18) Fewer lymphocytes in peripheral 
blood may represent early tissue infiltration of effector 
T cells and B cells, potentially due to genetic defects in 
apoptosis of activated immune cells.
11)19-23) Here, we test-
ed the usefulness of the Kobayashi score in Korean pa-
tients with KD, but a further multicenter study would 
further establish useful predictive factors. 
IVIG-resistant KD is characterized by prolonged fe-
ver and more severe coronary outcomes. Fever represents 
ongoing inflammatory reactions in vessels and may re-
flect defects in inhibition of immunologic stimuli.
24) Th-
erapies for IVIG-resistant KD could decrease inflamma-
tion and induce apoptosis of activated immune cells. Tr-
eatment with high dose corticosteroids improves fever 
and degradation of activated cells,
22)25) but there are few 
well-controlled prospective cohort studies. A tumor necro-
sis factor-α blocker
26) and low dose methotrexate
14)26)27) 
may also have therapeutic potential. The significance of 
coronary outcomes emphasizes the importance of early 
Table 2. Laboratory values in IVIG-responsive group and IVIG-resistant group in Kawasaki disease
Parameters  IVIG-responsive group (n=64)  IVIG-resistant group (n=13)  p 
Hemoglobin (g/dL)  11.7±1.2  11.2±1.3 0.262
Platelet count (count/ μ L)  416,000±173,000 342,000±150,000 0.131
Erythrocyte sedimentation rate (mm/hour)  63.4±37.4 71.7±48.0 0.567
C-reactive protein (mg/dL)  7.0±7.0 7.9±6.9 0.684
AST (IU/L)  46.5±33.2 78.0±87.7 0.226
ALT (IU/L)
  50.5±56.0  99.0±129.0 0.212
Albumin (g/dL)  4.0±0.4 3.6±0.6 0.025
Sodium (mEq/L)  137.9±3.6 135.5±3.9 0.049
Kobayashi scores*
  1.1±1.4 3.4±2.9 0.015
*Scores calculated by the methods by Kabayashi et al.
7) AST: aspartate aminotransferase, ALT: alanine aminotransferase, IVIG: intravenous 
immunoglobulin 
 
Table 3. Percentage of neutrophils and lymphocytes in IVIG-resistant group and IVIG-responsive group during acute phase and subacute 
phase of Kawasaki disease 
Acute phase 
Parameter 
IVIG-responsive group  IVIG-resistant group  Febrile control group  p
WBC count (count/ μ L) 13,400±6,000 14,200±5,400 13,500±7,300 0.915
% of neutrophils  55.4±20.0 67.0±18.5 56.2±21.0 0.163
% of lymphocytes  32.1±16.4 23.1±16.9 33.5±16.7 0.176
Sub-acute phase 
Parameter 
IVIG-responsive group  IVIG-resistant group  Febrile control group  p
WBC count (count/ μ L) 9,300±4,300 11,400±7,700 8,500±2,500 0.259
% of neutrophils  30.1±12.4 45.0±21.5 38.7±15.8 0.002
% of lymphocytes  52.8±13.6 41.5±19.2 47.0±15.0 0.032
IVIG: intravenous immunoglobulin, WBC: white blood cell 
 
Table 4. The serial incidence of coronary arterial dilatations in IVIG-responsive group and IVIG-resistant group in Kawasaki disease
Time of echocardiogram  IVIG-responsive group (%)  IVIG-resistant group (%)  p 
On admission  7/64 (10.9)  5/13 (38.5)  0.038
On 6 months  2/60 (3.3)  1/11 (9.9)  - 
On 1 year  1/40 (2.5)  1/10 (10)  - 
IVIG: intravenous immunoglobulin 
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aggressive management of IVIG-resistant KD. CAD oc-
curs significantly more frequently in IVIG-resistant KD 
than in the IVIG-responsive group.
28)29) This study also 
showed a higher incidence of CAD in the IVIG-resis-
tant group. Furthermore the sequelae of KD could be re-
lated with subclinical atherosclerosis in adolescence.
30)  
In conclusion, this study showed a high Kobayashi 
score during the acute phase and a relatively high pro-
portion of neutrophils and a low proportion of lymph-
ocytes during the subacute phase may predict IVIG-
resistant KD. Further, an expansive multicenter study is 
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